Your browser is no longer supported. Please, upgrade your browser.
UTHR United Therapeutics Corporation weekly Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E10.34 EPS (ttm)14.84 Insider Own0.10% Shs Outstand43.20M Perf Week7.47%
Market Cap6.63B Forward P/E10.71 EPS next Y14.32 Insider Trans-61.41% Shs Float41.66M Perf Month6.16%
Income708.00M PEG- EPS next Q3.61 Inst Own94.00% Short Float17.57% Perf Quarter31.18%
Sales1.59B P/S4.16 EPS this Y102.60% Inst Trans-0.13% Short Ratio12.03 Perf Half Y33.62%
Book/sh42.81 P/B3.58 EPS next Y-11.73% ROA32.00% Target Price131.75 Perf Year19.31%
Cash/sh23.90 P/C6.42 EPS next 5Y-2.30% ROE40.50% 52W Range97.52 - 154.84 Perf YTD6.98%
Dividend- P/FCF14.87 EPS past 5Y46.80% ROI19.10% 52W High-1.23% Beta1.40
Dividend %- Quick Ratio4.10 Sales past 5Y19.80% Gross Margin95.60% 52W Low56.82% ATR4.60
Employees750 Current Ratio4.40 Sales Q/Q5.70% Oper. Margin65.40% RSI (14)61.20 Volatility2.71% 2.98%
OptionableYes Debt/Eq0.00 EPS Q/Q-62.10% Profit Margin44.40% Rel Volume0.65 Prev Close153.44
ShortableYes LT Debt/Eq0.00 EarningsJan 26 BMO Payout0.00% Avg Volume608.54K Price152.93
Recom2.50 SMA204.63% SMA5010.98% SMA20025.80% Volume197,781 Change-0.33%
Jan-19-17Downgrade Standpoint Research Buy → Hold
Dec-15-16Initiated Oppenheimer Outperform
Oct-28-16Upgrade Ladenburg Thalmann Neutral → Buy
Jun-15-16Downgrade H.C. Wainwright Buy → Neutral $175 → $95
Apr-29-16Downgrade Ladenburg Thalmann Buy → Neutral
Apr-11-16Reiterated RBC Capital Mkts Sector Perform $150 → $122
Mar-28-16Reiterated Wedbush Outperform $238 → $229
Mar-02-16Reiterated Wedbush Outperform $244 → $238
Feb-10-16Upgrade Standpoint Research Hold → Buy $148
Jul-31-15Reiterated Argus Buy $205 → $200
Jul-29-15Reiterated RBC Capital Mkts Sector Perform $160 → $175
May-27-15Reiterated Argus Buy $195 → $205
Apr-29-15Reiterated RBC Capital Mkts Sector Perform $135 → $160
Mar-12-15Upgrade Argus Hold → Buy $195
Mar-04-15Downgrade Standpoint Research Buy → Hold
Feb-26-15Reiterated H.C. Wainwright Buy $150 → $175
Nov-03-14Downgrade Argus Buy → Hold
Oct-15-14Upgrade Standpoint Research Hold → Buy $144
Aug-29-14Reiterated Standpoint Research Buy $118 → $140
Jul-30-14Reiterated H.C. Wainwright Buy $120 → $150
Jan-19-17 12:33PM  United Therapeutics downgraded by Standpoint Research
Jan-11-17 11:10PM  D.C.-area biotech stocks fall on Trump's tough talk on industry at bizjournals.com -6.35%
03:24PM  VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan-05-17 08:27AM  New Strong Buy Stocks for January 5th
06:00AM  United Therapeutics Corporation To Present At 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-29-16 01:14PM  Vertex Pharmaceuticals Expects Strong Revenue Growth in 2016
10:10AM  United Therapeutics' PAH Suite Bodes Well, Competition Rife
09:06AM  United Therapeutics: Will RemoSynch Become a Key Growth Driver?
07:36AM  United Therapeutics Robust Research Pipeline
Dec-28-16 02:05PM  United Therapeutics: Will Orenitram See Strong Patient Demand?
12:35PM  United Therapeutics: Why Tyvaso Is Still a Key Growth Driver
10:55AM  Why United Therapeutics Expects Strong Revenue Growth
Dec-16-16 10:35AM  Dupixent Is Being Explored for Multiple Indications in 2016
Dec-12-16 04:21PM  The 3 Most Profit-Friendly Biotech Stocks at Motley Fool +5.51%
Dec-07-16 05:07PM  Are there buying opportunities in health care?
Dec-02-16 08:05AM  NBIX Continues to Study Valbenazine for Tourette Syndrome
04:29AM  Hedge Funds Are Selling Patterson Companies, Inc. (PDCO) at Insider Monkey
Dec-01-16 02:25PM  Pig organs to save lives by end of decade: United Therape...
11:32AM  Hedge Funds Are Buying WellCare Health Plans, Inc. (WCG) at Insider Monkey
Nov-30-16 11:17AM  What Happens When Your Biotech Stock Faces Generic Competition Lawsuits? at Motley Fool
Nov-25-16 08:32AM  J&J (JNJ) Reportedly Approaches Actelion for Acquisition
Nov-21-16 01:19PM  5 Most Expensive Medicare Drugs -- and Which Companies Are Getting Rich From Them at Motley Fool
Nov-09-16 04:29PM  How Greater Washington stocks fared post-election at bizjournals.com +7.16%
07:27AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : November 9, 2016
Nov-08-16 05:35PM  Palo Alto Investorss Bets on ABIOMED, Inc. (ABMD), United Therapeutics Corporation (UTHR) and Other Stocks Lift Its Q3 Returns at Insider Monkey
Nov-04-16 01:17AM  Mallinckrodt PLC (MNK) & Depomed Inc (DEPO) Helped Consonance Capital to Massive Q3 Returns at Insider Monkey
Nov-01-16 05:54PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors Accesswire
01:04PM  UNITED THERAPEUTICS CORP Financials
Oct-31-16 05:50PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of United Therapeutics Corporation -- UTHR Accesswire
01:06PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
10:39AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016
Oct-28-16 09:58AM  United Therapeutics (UTHR) Beats Q3 Earnings, Sales Miss
Oct-27-16 03:46PM  Edited Transcript of UTHR earnings conference call or presentation 27-Oct-16 1:00pm GMT
02:55PM  United Therapeutics upping the ante on R&D spending at bizjournals.com
09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today
07:07AM  Q3 2016 United Therapeutics Corp Earnings Release - Before Market Open
06:20AM  United Therapeutics beats 3Q profit forecasts
06:07AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:07AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report
06:00AM  United Therapeutics Corporation Reports Third Quarter 2016 Financial Results PR Newswire
Oct-26-16 07:25PM  6 Undervalued Stocks Trading Below the Peter Lynch Value
12:41PM  ETFs with exposure to United Therapeutics Corp. : October 26, 2016
Oct-21-16 09:13AM  Is a Surprise Coming for United Therapeutics (UTHR) This Earnings Season?
Oct-20-16 06:00AM  United Therapeutics Corporation To Report Third Quarter 2016 Financial Results Before The Market Opens On Thursday, October 27, 2016 PR Newswire
Oct-14-16 03:31PM  Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation at Motley Fool
Oct-13-16 09:46AM  Will These 5 Drug Stocks Be Big Winners This Earnings Season?
Oct-11-16 01:50PM  10 LGBT CEOs Who Weren't Afraid To Come Out
Oct-10-16 08:11AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : October 10, 2016
Oct-07-16 12:22PM  6 Healthcare Stocks Investors Can't Miss in Q3 Earnings
Oct-05-16 10:04AM  Top 5 Pharma stocks with strong earnings momentum. : October 5, 2016
Sep-29-16 10:19AM  United Therapeutics Corp. Value Analysis (NASDAQ:UTHR) : September 29, 2016
Sep-28-16 04:31PM  United Therapeutics Chilled On M&A Fever Amid Actelion, Bayer Rivalry
08:17AM  United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : September 28, 2016
06:44AM  5 Stocks with Exciting Price-to-Book Ratios
Sep-27-16 11:24AM  UNITED THERAPEUTICS CORP Files SEC form 8-K/A, Regulation FD Disclosure
10:29AM  Top 5 Pharma stocks by value : September 27, 2016
08:11AM  3 Great Stocks You Can Buy on Sale at Motley Fool
08:02AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
Sep-22-16 10:35AM  Analyst Has 3 Biotech Stocks to Buy With Over 100% Upside Potential at 24/7 Wall St.
Sep-01-16 08:04AM  How Analysts See United Therapeutics Continued Performance
Aug-31-16 11:58AM  ETFs with exposure to United Therapeutics Corp. : August 31, 2016
11:04AM  Physician and Payer Relationships to Increase UTHRs Drug Access
10:05AM  United Therapeutics Makes Novel Technologies a Priority
08:05AM  United Therapeutics Research Efforts Key to Boosting Stock
Aug-30-16 06:04PM  $1 Billion Sales Target in Place for Tyvaso
04:04PM  Generic Competition Not a Threat to UTHRs Remodulin
02:30PM  Strong Growth Projected for UTHRs Hypertension Drugs
02:30PM  Why UTHR Trades at Lower Multiples Compared to Its Peers
Aug-22-16 12:13PM  United Therapeutics Hurt By Competitive Pressure
Aug-20-16 12:05PM  This Company Could Grow Organs in the Lab -- and It's Not Organovo Holdings at Motley Fool
Aug-12-16 01:09PM  Analysts Recommendations for Celgene and Its Peers in 2016
01:09PM  How Do Celgenes Valuation Multiples Compare to Its Peers?
Aug-10-16 06:00AM  United Therapeutics Corporation To Present At The 2016 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-05-16 02:03PM  ETFs with exposure to United Therapeutics Corp. : August 5, 2016
Aug-04-16 10:14AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 4, 2016
Aug-03-16 06:44PM  These Five Stocks Show a Combination of Value and Growth
06:03PM  Worst Performance YTD: MasterCard, Lazard
03:29PM  5 Mid-Cap Stocks With Low Enterprise Multiples
11:04AM  Inside Amgens Analyst Recommendations for 2016
09:55AM  4 Biotech Stocks With Up to 300% Upside Potential and Upcoming Catalysts at 24/7 Wall St.
Jul-28-16 09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today +5.11%
07:07AM  Q2 2016 United Therapeutics Corp Earnings Release - Before Market Open
06:34AM  United Therapeutics tops Street 2Q forecasts
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 10-Q, Quarterly Report
06:00AM  United Therapeutics Corporation Reports Second Quarter 2016 Financial Results PR Newswire
Jul-22-16 01:12PM  What Do Analysts Recommend for United Therapeutics?
01:12PM  Will Orenitram Lose Market Share to Uptravi in 2016?
01:12PM  Tyvaso Sales Expected to Fall Marginally in 2Q16
08:50AM  Why United Therapeutics (UTHR) Might Surprise This Earnings Season
08:18AM  Martine Rothblatt: Organ manufacturing could make us the next Google at bizjournals.com
Jul-21-16 06:00AM  United Therapeutics Corporation To Announce Second Quarter 2016 Financial Results Before The Market Opens On Thursday, July 28, 2016 PR Newswire
Jul-20-16 04:13PM  How Will Remodulin Sales Fare in 2Q16?
04:13PM  United Therapeutics Expects to Report Strong 2Q16 Revenue Growth
Jul-19-16 01:14PM  CEO's message to investors: My biotech is like Google before it was big at CNBC
12:26PM  3 Biotech Stocks That Could Soar Over the Next 12 Months at Motley Fool
07:43AM  Medical 'moonshot': Manufactured organs
Jul-17-16 03:03PM  3 Biotech Stocks for Conservative Investors at Motley Fool
Jul-15-16 09:05AM  Coverage Initiated on Select Drug Manufacturer Stocks
Jul-14-16 09:05AM  ALNY Should Complete Revusirans Endeavour Trial Enrollment in Late 2016
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's principal therapeutic products and product candidates include Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH); Tyvaso, an inhaled prostacyclin therapy for PAH; Adcirca, a once-daily oral therapy for PAH; Orenitram, a prostacyclin analog for PAH; Unituxin, an antibody that binds to cancerous tumors and destroys the cancer cells; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & CEOJan 12Option Exercise30.751,21437,3311,354Jan 12 04:30 PM
ROTHBLATT MARTINE AChairman & CEOJan 12Option Exercise30.7596229,582640,364Jan 12 04:30 PM
PATUSKY CHRISTOPHERDirectorJan 12Option Exercise30.755,000153,7505,000Jan 12 04:32 PM
ROTHBLATT MARTINE AChairman & CEOJan 12Sale142.371,214172,840140Jan 12 04:30 PM
PATUSKY CHRISTOPHERDirectorJan 12Sale141.995,000709,9690Jan 12 04:32 PM
MAHON PAUL AEVP & General CounselJan 05Option Exercise50.096,000300,54041,221Jan 06 04:05 PM
CAUSEY CHRISTOPHERDirectorJan 05Option Exercise53.571,25066,9631,715Jan 06 04:06 PM
ROTHBLATT MARTINE AChairman & CEOJan 05Option Exercise30.751,20837,1461,348Jan 06 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJan 05Option Exercise30.7596929,797639,402Jan 06 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJan 05Sale145.731,208176,044140Jan 06 04:08 PM
ROTHBLATT MARTINE AChairman & CEODec 29Option Exercise30.751,21137,2381,351Jan 03 04:09 PM
ROTHBLATT MARTINE AChairman & CEODec 29Option Exercise30.7596529,674638,433Jan 03 04:09 PM
ROTHBLATT MARTINE AChairman & CEODec 29Sale143.631,211173,940140Jan 03 04:09 PM
ROTHBLATT MARTINE AChairman & CEODec 22Option Exercise30.751,21837,4541,358Dec 23 11:39 AM
ROTHBLATT MARTINE AChairman & CEODec 22Option Exercise30.7595929,489637,468Dec 23 11:39 AM
ROTHBLATT MARTINE AChairman & CEODec 22Sale140.231,218170,800140Dec 23 11:39 AM
MAHON PAUL AEVP & General CounselDec 15Option Exercise50.096,000300,54041,221Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 15Option Exercise30.751,21237,2691,352Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 15Option Exercise30.7596429,643636,509Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 15Sale143.111,212173,446140Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 08Option Exercise30.751,23638,0071,376Dec 09 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 08Option Exercise30.7594128,936650,528Dec 09 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 08Sale131.781,236162,875140Dec 09 04:05 PM
Giltner RichardDirectorDec 06Option Exercise41.145,000205,7005,000Dec 07 04:20 PM
Giltner RichardDirectorDec 06Sale133.375,000666,8450Dec 07 04:20 PM
CAUSEY CHRISTOPHERDirectorDec 01Option Exercise51.771,25064,7131,855Dec 02 04:15 PM
ROTHBLATT MARTINE AChairman & CEODec 01Option Exercise30.751,24638,3151,386Dec 02 04:20 PM
ROTHBLATT MARTINE AChairman & CEODec 01Option Exercise30.7593028,598649,587Dec 02 04:20 PM
MAHON PAUL AEVP & General CounselDec 01Option Exercise50.096,000300,54041,221Dec 02 04:19 PM
ROTHBLATT MARTINE AChairman & CEODec 01Sale126.861,246158,063140Dec 02 04:20 PM
ROTHBLATT MARTINE AChairman & CEONov 25Option Exercise30.751,23337,9151,373Nov 29 04:07 PM
ROTHBLATT MARTINE AChairman & CEONov 25Option Exercise30.7594429,028648,657Nov 29 04:07 PM
ROTHBLATT MARTINE AChairman & CEONov 25Sale132.811,233163,749140Nov 29 04:07 PM
MAHON PAUL AEVP & General CounselNov 17Option Exercise50.096,000300,54041,221Nov 21 04:09 PM
ROTHBLATT MARTINE AChairman & CEONov 17Option Exercise30.751,23237,8841,372Nov 18 04:14 PM
ROTHBLATT MARTINE AChairman & CEONov 17Option Exercise30.7594429,028647,713Nov 18 04:14 PM
ROTHBLATT MARTINE AChairman & CEONov 17Sale132.941,232163,779140Nov 18 04:14 PM
PATUSKY CHRISTOPHERDirectorNov 10Option Exercise30.755,000153,7505,000Nov 14 04:30 PM
ROTHBLATT MARTINE AChairman & CEONov 10Option Exercise30.751,24038,1301,380Nov 14 04:12 PM
ROTHBLATT MARTINE AChairman & CEONov 10Option Exercise30.7593728,813646,769Nov 14 04:12 PM
PATUSKY CHRISTOPHERDirectorNov 10Option Exercise30.755,000153,7505,000Nov 14 04:28 PM
PATUSKY CHRISTOPHERDirectorNov 10Option Exercise30.755,000153,7505,000Nov 14 04:31 PM
PATUSKY CHRISTOPHERDirectorNov 10Option Exercise30.755,000153,7505,000Nov 14 04:43 PM
PATUSKY CHRISTOPHERDirectorNov 10Sale131.425,000657,1230Nov 14 04:30 PM
ROTHBLATT MARTINE AChairman & CEONov 10Sale129.821,240160,978140Nov 14 04:12 PM
PATUSKY CHRISTOPHERDirectorNov 10Sale131.425,000657,1230Nov 14 04:28 PM
PATUSKY CHRISTOPHERDirectorNov 10Sale131.425,000657,1230Nov 14 04:31 PM
PATUSKY CHRISTOPHERDirectorNov 10Sale131.425,000657,1230Nov 14 04:43 PM
MAHON PAUL AEVP & General CounselNov 03Option Exercise50.096,000300,54041,221Nov 04 04:04 PM
CAUSEY CHRISTOPHERDirectorNov 03Option Exercise51.771,25064,7131,855Nov 04 04:04 PM
ROTHBLATT MARTINE AChairman & CEONov 03Option Exercise30.751,27239,1141,412Nov 04 04:05 PM
ROTHBLATT MARTINE AChairman & CEONov 03Option Exercise30.7590427,798645,832Nov 04 04:05 PM
ROTHBLATT MARTINE AChairman & CEONov 03Sale116.941,272148,750140Nov 04 04:05 PM
ROTHBLATT MARTINE AChairman & CEOOct 27Option Exercise30.751,27239,1141,412Oct 28 04:02 PM
ROTHBLATT MARTINE AChairman & CEOOct 27Option Exercise30.7590527,829644,928Oct 28 04:02 PM
ROTHBLATT MARTINE AChairman & CEOOct 27Sale117.061,272148,905140Oct 28 04:02 PM
MAHON PAUL AEVP & General CounselOct 21Option Exercise50.096,000300,54041,221Oct 21 04:24 PM
ROTHBLATT MARTINE AChairman & CEOOct 20Option Exercise30.751,28239,4221,422Oct 21 04:11 PM
ROTHBLATT MARTINE AChairman & CEOOct 20Option Exercise30.7589427,491644,023Oct 21 04:11 PM
ROTHBLATT MARTINE AChairman & CEOOct 20Sale113.301,282145,249140Oct 21 04:11 PM
ROTHBLATT MARTINE AChairman & CEOOct 13Option Exercise30.751,26939,0221,409Oct 17 04:08 PM
ROTHBLATT MARTINE AChairman & CEOOct 13Option Exercise30.7590827,921643,129Oct 17 04:08 PM
ROTHBLATT MARTINE AChairman & CEOOct 13Sale117.991,269149,736140Oct 17 04:08 PM
CAUSEY CHRISTOPHERDirectorOct 06Option Exercise51.771,25064,7132,355Oct 11 04:10 PM
MAHON PAUL AEVP & General CounselOct 06Option Exercise50.096,000300,54041,221Oct 11 04:11 PM
ROTHBLATT MARTINE AChairman & CEOOct 06Option Exercise30.751,26038,7451,400Oct 07 04:07 PM
ROTHBLATT MARTINE AChairman & CEOOct 06Option Exercise30.7591628,167642,221Oct 07 04:07 PM
ROTHBLATT MARTINE AChairman & CEOOct 06Sale121.171,260152,679140Oct 07 04:07 PM
ROTHBLATT MARTINE AChairman & CEOSep 29Option Exercise30.751,27239,1141,412Sep 30 04:11 PM
ROTHBLATT MARTINE AChairman & CEOSep 29Option Exercise30.7590527,829641,305Sep 30 04:11 PM
ROTHBLATT MARTINE AChairman & CEOSep 29Sale116.941,272148,743140Sep 30 04:11 PM
Thompson Tommy GDirectorSep 26Option Exercise48.111,29162,1101,291Sep 27 05:01 PM
Thompson Tommy GDirectorSep 26Sale125.571,291162,1110Sep 27 05:01 PM
ROTHBLATT MARTINE AChairman & CEOSep 22Option Exercise30.751,24938,4071,389Sep 26 04:31 PM
ROTHBLATT MARTINE AChairman & CEOSep 22Option Exercise30.7592728,505640,400Sep 26 04:31 PM
ROTHBLATT MARTINE AChairman & CEOSep 22Sale125.871,249157,208140Sep 26 04:31 PM
MAHON PAUL AEVP & General CounselSep 15Option Exercise50.096,000300,54041,221Sep 19 10:35 AM
ROTHBLATT MARTINE AChairman & CEOSep 15Option Exercise30.751,25838,6841,398Sep 19 10:34 AM
ROTHBLATT MARTINE AChairman & CEOSep 15Option Exercise30.7591928,259639,473Sep 19 10:34 AM
ROTHBLATT MARTINE AChairman & CEOSep 15Sale122.341,258153,909140Sep 19 10:34 AM
ROTHBLATT MARTINE AChairman & CEOSep 08Option Exercise30.751,25438,5611,394Sep 09 04:06 PM
ROTHBLATT MARTINE AChairman & CEOSep 08Option Exercise30.7592228,352638,554Sep 09 04:06 PM
ROTHBLATT MARTINE AChairman & CEOSep 08Sale123.441,254154,798140Sep 09 04:06 PM
MAHON PAUL AEVP & General CounselSep 01Option Exercise50.096,000300,54041,221Sep 02 04:09 PM
CAUSEY CHRISTOPHERDirectorSep 01Option Exercise51.771,25064,7132,355Sep 02 04:08 PM
PATUSKY CHRISTOPHERDirectorSep 01Option Exercise30.755,000153,7505,000Sep 02 04:10 PM
ROTHBLATT MARTINE AChairman & CEOSep 01Option Exercise30.751,25738,6531,397Sep 02 04:11 PM
ROTHBLATT MARTINE AChairman & CEOSep 01Option Exercise30.7592028,290637,632Sep 02 04:11 PM
PATUSKY CHRISTOPHERDirectorSep 01Sale122.735,000613,6270Sep 02 04:10 PM
ROTHBLATT MARTINE AChairman & CEOSep 01Sale122.811,257154,378140Sep 02 04:11 PM
ROTHBLATT MARTINE AChairman & CEOAug 25Option Exercise30.751,25038,4381,390Aug 26 04:15 PM
ROTHBLATT MARTINE AChairman & CEOAug 25Option Exercise30.7592628,475636,712Aug 26 04:15 PM
ROTHBLATT MARTINE AChairman & CEOAug 25Sale125.291,250156,608140Aug 26 04:15 PM
ROTHBLATT MARTINE AChairman & CEOAug 18Option Exercise30.751,24938,4071,389Aug 19 04:16 PM
ROTHBLATT MARTINE AChairman & CEOAug 18Option Exercise30.7592828,536635,786Aug 19 04:16 PM
MAHON PAUL AEVP & General CounselAug 18Option Exercise50.096,000300,54041,221Aug 22 09:26 AM
ROTHBLATT MARTINE AChairman & CEOAug 18Sale125.881,249157,223140Aug 19 04:16 PM
ROTHBLATT MARTINE AChairman & CEOAug 11Option Exercise30.751,25338,5301,393Aug 15 09:50 AM
ROTHBLATT MARTINE AChairman & CEOAug 11Option Exercise30.7592328,382634,858Aug 15 09:50 AM
ROTHBLATT MARTINE AChairman & CEOAug 11Sale124.091,253155,487140Aug 15 09:50 AM